FDA regulation of Artificial Intelligence (AI) and Machine Learning (ML) follows a risk-based framework focused on safety and effectiveness throughout the product lifecycle. As of mid-2025, the FDA has authorized over 1,250 AI-enabled medical devices, with nearly 80% used in radiology .
The biopharmaceutical industry operates within a complex web of regulatory requirements, demanding meticulous attention to quality and compliance at every stage of a project. From early-stage research to commercial manufacturing, deviations can have significant consequences, impacting patient safety, product efficacy, and the company’s reputation. Optimizing quality and compliance is not merely about ticking boxes; it’s a strategic imperative that drives efficiency, reduces risks, and fosters innovation.